Developing a low-cost method for detecting proteins in diseases like Alzheimer's and AIDS
Official title: Low-Cost Platform for Ultrasensitive Fluorescent Immunoblot
Funded at Auragent Bioscience, LLC · NIH-11008719 · Data updated 2026-11-12
This study is working on a new, affordable way to test for important proteins linked to diseases like Alzheimer's and AIDS, which could help doctors find these proteins more accurately and lead to better treatments for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Auragent Bioscience, LLC NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project start | September 25, 2024 |
| Project end | August 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $986,651 |
| NIH project number | 1R44GM156258-01 |
| Project ID | NIH-11008719 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or AIDS who may benefit from improved diagnostic methods.
✕Less likely to help
Patients with conditions unrelated to protein detection or those who do not require diagnostic testing may not receive benefits from this research.
What this research studies
This research focuses on creating a cost-effective platform for fluorescent immunoblot assays, which are essential for detecting and quantifying proteins related to various diseases, including Alzheimer's and AIDS. The approach aims to enhance the sensitivity of these assays, allowing for the detection of low concentrations of proteins and their modified forms. By improving the accuracy and efficiency of protein detection, this research could significantly advance our understanding of disease mechanisms and treatment responses. Patients may benefit from more precise diagnostic tools that can lead to better-targeted therapies.
Why it matters
Potential benefit: If successful, this research could provide patients with more accurate and sensitive diagnostic tests for conditions like Alzheimer's and AIDS.
How similar studies have gone: Other research has shown success in enhancing protein detection methods, indicating that this approach has the potential for significant advancements.
Where this research is happening
-
Auragent Bioscience, LLC
Saint Louis, United States Active
Researchers
- Principal investigator: Crick, Scott L — Auragent Bioscience, LLC
- Study coordinator: Crick, Scott L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.